Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Impact of Absolute Lymphocyte Count at Pre-Apheresis and Pre-Lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 1944.

https://doi.org/10.1182/blood-2024-208490

Published: 2024

Journal Articles

Impact of Daratumumab Refractoriness on Clinical Outcomes Following CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7090.

https://doi.org/10.1182/blood-2024-206511

Published: 2024

Journal Articles

Infectious Complications during Treatment with Commercial CAR T-Cell Therapy and Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 6935.

https://doi.org/10.1182/blood-2024-207977

Published: 2024

Journal Articles

Comparison of Acute Kidney Injury in Patients with Relapsed or Refractory Multiple Myeloma Following CAR T-Cell and Bispecific Antibody Therapies

Blood (2024) 144 (Supplement 1): 6944.

https://doi.org/10.1182/blood-2024-212006

Published: 2024

Journal Articles

CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes

Blood (2024) 144 (Supplement 1): 912.

https://doi.org/10.1182/blood-2024-203520

Published: 2024

Journal Articles

A Comparative Analysis of Infectious Complications in Patients with Multiple Myeloma Treated with BCMA-Targeted Bispecific Antibodies and CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 1957.

https://doi.org/10.1182/blood-2023-179413

Published: 2023

Journal Articles

Stem Cell Utilization in the Era of Novel Therapies for Multiple Myeloma

Blood (2023) 142 (Supplement 1): 2219.

https://doi.org/10.1182/blood-2023-188103

Published: 2023

Journal Articles

Stem Cell Autograft Minimal Residual Disease Negativity Improves Outcomes after Autotransplant for Multiple Myeloma

Blood (2022) 140 (Supplement 1): 620–622.

https://doi.org/10.1182/blood-2022-160271

Published: 2022

Journal Articles

Serum Cell-Free DNA Concentration Is Predictive of Survival Outcomes and Its Genetic Mutation Analysis May Be Viable in Obtaining Pathological Information

Yuko Shirouchi, MD, Yuko Mishima, MD PhD, Yuji Mishima, PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Hideki Uryu, MD, Takashi Okabe, MD, Norihito Inoue, MD, Takanori Fukuta, MD, Kiyohiko Hatake, MD PhD, Yasuhito Terui, MD PhD

Blood (2019) 134 (Supplement_1): 1498.

https://doi.org/10.1182/blood-2019-125096

Published: 2019

Journal Articles

Impact of Continuous and Maintenance Therapy on Survival Outcome in Patients with Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Shuji Ozaki, MD PhD, Hiroshi Handa, MD PhD, Takayuki Saitoh, MD PhD, Kazutaka Sunami, MD PhD, Tadao Ishida, MD PhD, Kenshi Suzuki, MD PhD, Tomoko Narita, MD, Shinsuke Iida, MD PhD, Yuichi Nakamura, MD PhD, Kazuhito Suzuki, MD, Noriko Nishimura, MD PhD, Hirokazu Murakami, MD PhD, Kazuyuki Shimizu, MD

Blood (2019) 134 (Supplement_1): 3085.

https://doi.org/10.1182/blood-2019-125390

Published: 2019

Journal Articles

Cell-Free DNA Genotyping Analysis in Diffuse Large B-Cell Lymphoma; The Correlation between TP53 Gene Mutation and Cereblon Gene Mutation

Hideki Uryu, MD, Yuko Mishima, MD PhD, Yuji Mishima, PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Takashi Okabe, MD, Norihito Inoue, MD, Takanori Fukuta, MD, Yuko Shirouchi, MD, Kiyohiko Hatake, MD PhD, Yasuhito Terui, MD PhD

Blood (2019) 134 (Supplement_1): 2786.

https://doi.org/10.1182/blood-2019-122920

Published: 2019

Journal Articles

The Necessary for Long-Term Follow-up of Mutated Genes and Clonal Evolutions in Multiple Myeloma Combined with cfDNA Assay

Yuko Mishima, MD PhD, Yuji Mishima, PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Norihito Inoue, MD, Hideki Uryu, MD, Takanori Fukuta, MD, Yuko Shirouchi, MD, Kiyohiko Hatake, MD PhD, Yasuhito Terui, MD PhD

Blood (2019) 134 (Supplement_1): 5515.

https://doi.org/10.1182/blood-2019-122977

Published: 2019

Journal Articles

Impact of Creatinine Clearance in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP : A Real-World Long-Term Observation Analysis at a Single Institute

Noriko Nishimura, MD PhD, Takanori Fukuta, MD, Anna Nishihara, MD, Yuko Shirouchi, MD, Hideki Uryu, MD, Norihito Inoue, MD, Yoshiharu Kusano, MD, Naoko Tsuyama, MD PhD, Kengo Takeuchi, MD PhD, Yuko Mishima, MD PhD, Masahiro Yokoyama, MD, Yasuhito Terui, MD PhD

Blood (2018) 132 (Supplement 1): 5399.

https://doi.org/10.1182/blood-2018-99-115897

Published: 2018

Journal Articles

The Prognostic Significance of Soluble Interleukin-2-Receptor, Beta-2-Microgrobulin and Serum Albumin in Patient with Diffuse Large B-Cell Lymphoma in the Rituximab Era

Norihito Inoue, MD, Masahiro Yokoyama, MD, Yuko Shirouchi, MD, Takanori Fukuta, MD, Anna Nishihara, MD, Yoshiharu Kusano, MD, Hideki Uryu, MD, Yuko Mishima, MD PhD, Noriko Nishimura, MD PhD, Naoko Tsuyama, MD PhD, Kengo Takeuchi, MD PhD, Yasuhito Terui, MD PhD

Blood (2018) 132 (Supplement 1): 4242.

https://doi.org/10.1182/blood-2018-99-115863

Published: 2018

Journal Articles

B-Symptoms, Performance Status and Response to First Therapy As Survival Predictive Factors for Peripheral T-Cell Lymphoma at Progression/Relapse: A Single Institute Analysis

Yuko Shirouchi, MD, Takanori Fukuta, MD, Anna Nishihara, MD, Norihito Inoue, MD, Hideki Uryu, MD, Yoshiharu Kusano, MD, Noriko Nishimura, MD PhD, Yuko Mishima, MD PhD, Masahiro Yokoyama, MD, Naoko Tsuyama, MD PhD, Kengo Takeuchi, MD PhD, Yasuhito Terui, MD PhD

Blood (2018) 132 (Supplement 1): 5360.

https://doi.org/10.1182/blood-2018-99-112038

Published: 2018

Journal Articles

The Prognosis of Transformed DLBCL Were Superior to De Novo DLBL after the Relapsed/Refractory Status Related to the MYC Translocation

Yuko Mishima, PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Hideki Uryu, MD, Norihito Inoue, MD, Anna Nishihara, MD, Takanori Fukuta, MD, Yuko Shirouchi, MD, Naoko Tsuyama, MD PhD, Kengo Takeuchi, MD PhD, Yasuhito Terui, MD PhD

Blood (2018) 132 (Supplement 1): 5417.

https://doi.org/10.1182/blood-2018-99-111081

Published: 2018

Journal Articles

Efficacy of Rituximab Maintenance for Diffuse Large B Cell Lymphoma with Transformation

Hideki Uryu, MD, Yuko Mishima, MD PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Norihito Inoue, MD, Anna Nishihara, MD, Takanori Fukuta, MD, Yuko Shirouchi, MD, Naoko Tsuyama, MD PhD, Kengo Takeuchi, MD PhD, Yasuhito Terui, MD PhD

Blood (2018) 132 (Supplement 1): 4229.

https://doi.org/10.1182/blood-2018-99-111513

Published: 2018

Journal Articles

The Role of Image Surveillance in Patients with Diffuse Large B-Cell Lymphoma: A Single-Center Validation Study

Takanori Fukuta, MD, Noriko Nishimura, MD PhD, Yuko Shirouchi, MD, Anna Nishihara, MD, Norihito Inoue, MD, Hideki Uryu, MD, Yoshiharu Kusano, MD, Yuko Mishima, MD PhD, Naoko Tsuyama, MD PhD, Kengo Takeuchi, MD PhD, Masahiro Yokoyama, MD, Yasuhito Terui, MD PhD

Blood (2018) 132 (Supplement 1): 2989.

https://doi.org/10.1182/blood-2018-99-113984

Published: 2018

Journal Articles

Poor Prognosis of CD5 Positive with Non Germinal Center Type of Diffuse Large B Cell Lymphoma Especially Having the Aberration of 19q13

Yuko Mishima, PhD, Yasuhito Terui, MD PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Yamauchi Hirofumi, MD, Norihito Inoue, MD, Anna Nishihara, MD, Naoko Tsuyama, MD PhD, Yuji Mishima, PhD, Kengo Takeuchi, MDPhD, Kiyohiko Hatake, MD PhD

Blood (2017) 130 (Supplement 1): 4153.

https://doi.org/10.1182/blood.V130.Suppl_1.4153.4153

Published: 2017

Journal Articles

Rituximab Combined Therapy and Maintenance Eliminate the Follicular Lymphoma with MYC Translocation

Anna Nishihara, MD, Yuko Mishima, PhD, Tomoko Takayama, Yasuhito Terui, MD PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Hirofumi Yamauchi, MD, Norihito Inoue, MD, Naoko Tsuyama, MD PhD, Yuji Mishima, PhD, Kengo Takeuchi, MDPhD, Kiyohiko Hatake, MD PhD

Blood (2017) 130 (Supplement 1): 2784.

https://doi.org/10.1182/blood.V130.Suppl_1.2784.2784

Published: 2017

NARROW

Impact of Absolute Lymphocyte Count at Pre-Apheresis and Pre-Lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)

Impact of Daratumumab Refractoriness on Clinical Outcomes Following CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma

Infectious Complications during Treatment with Commercial CAR T-Cell Therapy and Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma

Comparison of Acute Kidney Injury in Patients with Relapsed or Refractory Multiple Myeloma Following CAR T-Cell and Bispecific Antibody Therapies

CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes

A Comparative Analysis of Infectious Complications in Patients with Multiple Myeloma Treated with BCMA-Targeted Bispecific Antibodies and CAR T-Cell Therapy

Stem Cell Utilization in the Era of Novel Therapies for Multiple Myeloma

Stem Cell Autograft Minimal Residual Disease Negativity Improves Outcomes after Autotransplant for Multiple Myeloma

Serum Cell-Free DNA Concentration Is Predictive of Survival Outcomes and Its Genetic Mutation Analysis May Be Viable in Obtaining Pathological Information

Impact of Continuous and Maintenance Therapy on Survival Outcome in Patients with Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Cell-Free DNA Genotyping Analysis in Diffuse Large B-Cell Lymphoma; The Correlation between TP53 Gene Mutation and Cereblon Gene Mutation

The Necessary for Long-Term Follow-up of Mutated Genes and Clonal Evolutions in Multiple Myeloma Combined with cfDNA Assay

Impact of Creatinine Clearance in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP : A Real-World Long-Term Observation Analysis at a Single Institute

The Prognostic Significance of Soluble Interleukin-2-Receptor, Beta-2-Microgrobulin and Serum Albumin in Patient with Diffuse Large B-Cell Lymphoma in the Rituximab Era

B-Symptoms, Performance Status and Response to First Therapy As Survival Predictive Factors for Peripheral T-Cell Lymphoma at Progression/Relapse: A Single Institute Analysis

The Prognosis of Transformed DLBCL Were Superior to De Novo DLBL after the Relapsed/Refractory Status Related to the MYC Translocation

Efficacy of Rituximab Maintenance for Diffuse Large B Cell Lymphoma with Transformation

The Role of Image Surveillance in Patients with Diffuse Large B-Cell Lymphoma: A Single-Center Validation Study

Poor Prognosis of CD5 Positive with Non Germinal Center Type of Diffuse Large B Cell Lymphoma Especially Having the Aberration of 19q13

Rituximab Combined Therapy and Maintenance Eliminate the Follicular Lymphoma with MYC Translocation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only